Mitchell Lawrence Jones
President & Chief Medical OfficerDr. Mitchell Lawrence Jones, MD, PhD, also known as Mitch, serves as President & Chief Medical Officer at Palisade Bio, Inc. since December 2025 and served as its Chief Operating Officer since September 05, 2023 until December 2025.He was Vice President of Corporate Development and Strategy at Chemomab Therapeutics Ltd. since November 2022. He served as a Co-Founder and Chief Scientific Officer of Micropharma Limited. Dr. Jones served as a consultant for Novome Biotechnologies, Inc. and xBiome, Inc. He has been with the Micropharma Limited since its inception and is the driving force behind Micropharma’s innovation and R&D. He has pioneered novel probiotic selection assays and methods for development which form the basis for the Micropharma's rapidly growing product pipeline. He most recently served as Vice President Clinical Discovery and Development at Nasdaq-listed Finch Therapeutics, where he contributed to a successful IPO and helped oversee the clinical development of novel therapeutics for treating inflammatory bowel disease and cancer. Prior to Finch, he served as Vice President of Translational and Clinical Development at Nasdaq-listed Biora Therapeutics (formerly known as Progenity) from May 2015 to July 2020. Previously, he served as Vice President, Innovation and Clinical Translational Development, helping to formulate and implement a strategic roadmap encompassing all aspects of the business while contributing to both venture financing and the company's subsequent IPO. Earlier, he helped establish and then managed the successful trade sale of the technology platform and assets of Interface Biosciences. He is well published in peer reviewed journals and has submitted 40 patent applications. He has been instrumental in raising public research support and has secured two successful NRC-IRAP applications awarded to the Micropharma Limited in 2008 for the development of a microencapsulated nitric oxide producing agent containing topical medical device and in 2011 for the development of an oral bacterial formulation for the treatment of diabetes and pre-diabetes. Further, he has successfully collaborated and sponsored four NSERC Engage grants with academic researchers in various fields of natural science and engineering. Throughout his career, he has been the recipient of several prestigious awards for excellence in academics, research and innovation including the Alexander Graham Bell Scholarship, Geddes Prize in Biomedical Engineering, Dean’s Honor List, NSERC PGSA Postgraduate Scholarship and Martlett Scholarship. He was trained at McGill University, where he holds Degrees in Human Physiology (B Sc), Biomedical Engineering (M Eng and PhD) as well as in Clinical Medicine (MD).
Positions
- Company NamePalisade Bio, Inc.Stock CodePALIPositionPresident & Chief Medical OfficerColleagues
- JDJ. D. FinleyCEO, CFO & Director
- DADonald A. WilliamsIndependent Chairman of the Board
- RCRamesh C. DonthamsettyHead of IR and Corporate Strategy
- JEJulien E. CapersGeneral Counsel & Corporate Secretary
- JHJoerg HeyerHead of Translational Science & Medicine
- ECEmil ChuangIndependent Director
- BWBinxian WeiIndependent Director
- BEBruce E. SandsMember of Clinical Advisory Board
